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Abstract A cDNA clone for an inhibitor of Bombyx cysteine
proteinase was isolated and sequenced. Active inhibitor proteins
were expressed in Escherichia coli using the cDNA. The open
reading frame of the cDNA encodes a 105 residues protein with
19 residues of a signal sequence. The inhibitor has amino acid
sequences homologous to several cysteine proteinases, but only to
their propeptide sequences. The results suggest that some
cysteine proteinase proregions may have evolved as autonomous
modules and become inhibitor proteins for cysteine proteinases.
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1. Introduction
Protein inhibitors of cysteine proteinases have been re-
ported in various kinds of organisms and cystatins and the
cystatin superfamily have been studied extensively [1^3]. A
large amount of cysteine proteinase (BCP: Bombyx cysteine
proteinase) which belongs to a papain superfamily accumu-
lates as an enzymatically inactive pro-form in eggs and hemo-
lymph of the silkmoth Bombyx mori [4,5]. Recently, we found
and puri¢ed two forms of inhibitor proteins inhibiting the
BCP (BCPI: BCP inhibitor), designated BCPI K and BCPI
L, from the hemolymph of the silkmoth (Yamamoto et al.,
submitted). Both forms of inhibitor were inhibitory towards
other cysteine proteinases such as papain, cathepsin L and B,
but had no e¡ects on trypsin and pepsin. Here, we isolated a
cDNA clone for one of the inhibitor proteins and determined
its nucleotide sequence. We also expressed the inhibitor in
Escherichia coli and obtained active proteins. The deduced
amino acid sequence of the inhibitor is signi¢cantly homolo-
gous to those of several cysteine proteinases, more precisely
and most interestingly to the propeptide sequences of these
enzymes. We present here a novel cysteine proteinase inhibitor
which is homologous to the proregion of cysteine proteinases.
There has been one report about proteins homologous to
cysteine proteinase proregions [6]. Denizot, F. et al. have re-
ported that two proteins, CTLA-2 K and CTLA-2 L, ex-
pressed in mouse activated T-cells and mast cells, are homol-
ogous to cysteine proteinase proregions. They have proposed
that some cysteine proteinase proregions may have evolved as
autonomous modules. The report presented here may be the
second presentation which strongly supports their proposal.
2. Materials and methods
2.1. cDNA cloning
Routine molecular cloning techniques were used [7]. Inhibitor
cDNAs were ampli¢ed using PCR techniques with the ‘Marathon
TM cDNA ampli¢cation kit (Clontech)’ according to the user man-
ual. mRNA was puri¢ed from fat bodies of the spinning Bombyx
pupae. cDNA was synthesized and the speci¢c adaptor DNAs sup-
plied in the kit were ligated to both its ends. 5P and 3P rapid ampli-
¢cation of cDNA ends (RACE) reactions were performed with a
combination of gene-speci¢c primer and the adaptor primer using
‘touchdown PCR’ techniques suggested by the manual [8]. Two kinds
of gene-speci¢c primers (5P RACE primer and 3P RACE primer) were
designed on the basis of the amino acid sequences obtained by amino
acid sequencing of the puri¢ed inhibitor as shown in Fig. 1. To gen-
erate a full length cDNA, 5P and 3P cDNA clones were ampli¢ed by
the second PCR with the adaptor primer and the corresponding gene-
speci¢c primer using the adaptor ligated cDNA. Gene-speci¢c primers
used for the second PCR (5P cDNA primer and 3P cDNA primer)
were designed on the basis of the sequence of the 5P and 3P RACE
clones which had been con¢rmed to be real by a nucleotide sequence
analysis (Figs. 1 and 2). The nucleotide sequence analysis was per-
formed by the dideoxy method of Sanger et al. [9], with a Hitachi
Fluorescence DNA Sequencer (Hitachi, SQ-5500).
2.2. Expression of inhibitor in E. coli
cDNA constructs for expression in E. coli were ampli¢ed from an
inhibitor cDNA covering the entire encoding region by PCR techni-
ques. The primers used were designed on the basis of the cDNA
sequence with additional restriction enzyme sites of BamHI. The am-
pli¢ed DNA fragments were digested with BamHI and ligated into
pET20b (Novagen) cut with BamHI. Ligated products were trans-
formed ¢rst into E. coli XL1-Blue (Stratagene) and suitable clones
were selected. Plasmids were then transferred to expression host
strains E. coli BL21(DE3)pLysS. Expression was induced by isoprop-
yl-L-D-thiogalactopyranoside (IPTG) and proteins from the periplasm
were isolated with the osmotic shock procedure according to the ‘pET
System Manual (Novagen)’.
2.3. Other methods
The inhibition activity was measured with a procedure essentially
the same as that for the BCP assay described previously [10]. The
reaction mixture contained (in 300 Wl) 100 mM sodium acetate bu¡er
(pH 5.5), 1 mM EDTA, 8 mM cysteine, 10 WM Z-Phe-Arg-MCA
(Peptide Institute), 30 ng of activated BCP and inhibitor proteins.
After a short incubation (at 37‡C for 5^10 min), the reaction was
stopped and the remaining BCP activity was measured £uorometri-
cally. Control mixtures containing no inhibitors (0% inhibition) were
always taken in each assay. One unit of inhibitor activity was de¢ned
as the amount causing 50% inhibition of the BCP activity under the
condition. SDS-PAGE and Western blotting analysis using a speci¢c
antibody against the inhibitor were carried out by as described pre-
viously in Section 2 [4,5]. A Northern blot analysis to determine the
size of the inhibitor mRNA was carried out on poly (A) RNA, ex-
tracted from the fat bodies of the spinning pupae by hybridizing to a
near full length inhibitor cDNA probe [5]. A sequence homology
analysis of the GenBank data base was performed using the National
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Center for Biotechnology Information (NCBI) BLAST network serv-
ice with the BLAST algorithm.
3. Results
3.1. Cloning and analysis of cDNA encoding inhibitor
After the ¢rst PCR ampli¢cation, 5P and 3P RACE products
yielded two bands (1100 and 300 bp) and one band (350 bp)
on agarose gel electrophoresis, respectively. At sequencing of
the cloned cDNAs, a 5P RACE clone (300 bp) and a 3P RACE
clone (350 bp) were identi¢ed with a signi¢cant homology to
the amino acid sequences of the inhibitor. By the second PCR
ampli¢cation following subcloning into the cloning vectors,
two cDNA clones (5P and 3P cDNA) were isolated. The clones
obtained and sequenced are presented in Fig. 1. To minimize
sequencing errors caused by PCR artifacts (misreading by
polymerase), at least three independent clones for each PCR
product were isolated and sequenced in both orientations.
Since the sequence of the 3P end of the 5P cDNA clone per-
fectly matched to the 5P end sequence of the 3P cDNA clone, it
was possible to de¢ne a full length cDNA clone by combining
the 5P and 3P cDNA clones (Fig. 2). The cDNA contained 522
nucleotides with a polyadenylation site (AATAAA) at 12 nu-
cleotides upstream of the poly (A) tail. There was an open
reading frame of 315 nucleotides encoding a 105 residue pro-
tein. Amino acid sequences of the N-terminal and Lys-C-di-
gested peptides of the puri¢ed inhibitor matched well with the
deduced amino acid sequence. The ¢rst 19 amino acid residues
of the open reading frame seem to constitute the signal pep-
tide according to the matching in the N-terminal amino acid
sequence and theoretical considerations [11]. Two kinds of
inhibitors (BCPI K and L) which are closely related but di¡er
in the N-terminal amino acid sequences have been character-
ized in B. mori (Yamamoto et al., submitted). The deduced
amino acid sequence indicates that the cDNA obtained here
corresponds to the L form, the major form of the inhibitors.
Northern blotting and hybridization using a cDNA fragment
revealed the presence of a single mRNA of 580 bp for the
inhibitor (Fig. 3).
3.2. Expression of a recombinant inhibitor in E.coli
In order to con¢rm that the protein encoded by the inhib-
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Fig. 1. Cloning strategy of cDNA clones of the BCP inhibitor. Synthesized cDNA was ligated with adaptor DNAs (black box) to create a pop-
ulation of cDNAs, from which speci¢c cDNAs were ampli¢ed by PCR using di¡erent sets of gene-speci¢c primers (5P RACE primer, 3P RACE
primer, 5P cDNA primer, 3P cDNA primer) and adaptor primers (AP: 5P-CCATCCTAATACGACTCACTATAGGGC-3P). The light shadowed
box indicates the amino acid encoding region.
Fig. 2. The nucleotide sequence and deduced amino acid sequence
of the BCP inhibitor. Amino acid sequences determined by protein
sequencing are underlined. Nucleotide sequences shown by the
underlinings were used to design primers for the second PCR. An
arrow indicates a cleavage site in post-translational processing. A
single asterisk indicates the termination codon and the polyadenyla-
tion signal is boxed.
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itor cDNA is really the BCP inhibitor, the protein was ex-
pressed in E. coli. We constructed a cDNA encoding the 86
amino acid residues (from Glu-20 to Thr-105) and lacking the
amino acid sequence of the signal peptide of the inhibitor. The
construct was ligated into an expression vector, in the site
downstream of the sequence encoding the E. coli N-terminal
signal sequence (pelB leader), which allowed the periplasmic
localization of the fusion protein in E. coli. On an electro-
phoresis of the total protein from the E. coli transformed
with a plasmid containing the inhibitor cDNA (pET20bBC-
PI), an additional protein band with an approximate molec-
ular mass of 13 kDa was observed (Fig. 4a). The molecular
mass coincides with the value estimated for the fused protein.
A Western blotting analysis using speci¢c antiserum against
the inhibitor protein also indicates that the protein expressed
is a fused protein with the inhibitor (Fig. 4b). Inhibitory ac-
tivities against BCP were measured for extracts from the
transformed cells. A signi¢cant activity (2870 U/mg protein)
was detected in the extract containing the fused protein,
whereas no activity was detected in the extract from cells
with control vector (pET20b). Consequently, all of these
data indicate that the cDNA we have presented and charac-
terized corresponds to the inhibitor puri¢ed from B. mori.
3.3. Comparison of the inhibitor amino acid sequence with other
proteins
A search in the GenBank sequence data base showed that
the inhibitor contained sequence regions homologous to the
propeptide sequences of cysteine proteinases (Fig. 5). The de-
duced amino acid sequence of the inhibitor was 28% identical
(29/105 matches) to that of Cydia pomonella granulovirus
cathepsin in the proregion [12] and showed a lower resem-
blance (23^25% identity) to the sequences of cathepsins
from the other baculoviruses of Choristoneura fumiferana
[13] and B. mori [14]. The amino acid sequence of the inhibitor
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Fig. 4. SDS-PAGE analysis of BCP inhibitor expressed in E. coli.
Total cell extracts from BL21(DE3)pLysSpET20b (lanes 1, 3) and
BL21(DE3)pLysSpET20bBCPI (lanes 2, 4) were subjected to SDS-
PAGE, following staining with Coomassie brilliant blue R250 (a)
and immune staining with anti-BCP inhibitor serum (b). Sd, protein
molecular weight standards.
Fig. 5. Comparison of the amino acid sequence of BCP inhibitor
with the propeptide sequences of related cysteine proteinases. The
sequence of the BCP inhibitor was aligned with each of the other
sequences by use of gaps to achieve maximal alignment. Numbers
refer to the pre-propeptide sequence of papain. Residues that are
identical to amino acid residues in the BCP inhibitor are indicated
by black boxes and gaps are represented by dashes. Italics show sig-
nal peptides. BCPI, BCP inhibitor; CpGV, Cydia pomonella granu-
lovirus cathepsin [12], g, AB010886; Phaseolus, Phaseolus vulgaris
cysteine proteinase precursor, g, Z99952; Arabidopsis, Arabidopsis
thaliana cysteine proteinase-like protein, g, AL022604; Pisum, Pisum
sativum thiolprotease, g, X66061; CfNPV, Choristoneura fumiferana
nucleopolyhedrovirus cathepsin L [13], g, P41715; BmNPV, Bombyx
mori nucleopolyhedrovirus cysteine protease [14], g, U12688; Plas-
modium, Plasmodium fragile cysteine proteinase [16], g, U33421;
Trypanosoma, Trypanosoma congolense cysteine proteinase, g,
S37048; Papain, Carica papaya papaya proteinase I [15], g, P00784;
g, abbreviation of GenBank database accession number.
Fig. 3. Northern blot hybridization analysis. Poly (A) RNA (lane 1,
1 Wg; lane 2, 2 Wg) from fat bodies of spinning pupae were ana-
lyzed. A cDNA fragment (81^397) was used as a probe. Arrows in-
dicate molecular weights estimated from a RNA marker (Novagen).
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was also homologous to those of plant cysteine proteinases,
with 27% identity for Phaseolus vulgaris cysteine proteinase,
28% identity for Arabidopsis thaliana cysteine proteinase-like
protein, 27% identity for Pisum sativum thiolprotease and 21%
identity for Carica papaya papain precursor [15]. The inhib-
itor was on average less homologous to protozoan cysteine
proteinases, with 21% identity for Plasmodium fragile cysteine
proteinase [16] and 18% identity for Trypanosoma congolense
cysteine proteinase. Homology was not existent for the N-
terminal ends which constitute signal peptides.
4. Discussion
Sequence comparison revealed that BCP inhibitor is not
homologous to cystatin type inhibitors. The deduced amino
acid sequence of the inhibitor was signi¢cantly homologous to
the proregions of several cysteine proteinase precursors. The
degree of identity is not high but almost the same identity has
been observed when the proregions of cysteine proteinases are
compared. The homology analysis of cysteine proteinases has
revealed that the propeptide regions show a signi¢cant but
low sequence homology, it amounts to 22^34% identity,
although the mature regions of the proteinases show a very
high sequence homology (30^60% identity) [17]. The protein
sequence of CTLA-2 L is 36% identical to the proregion of
mouse cathepsin L. The CTLA-2 L was expressed in the ba-
culovirus system and the expressed protein has been biochemi-
cally characterized, showing that the protein is a competitive
inhibitor of certain cysteine proteinases including papain,
cathepsin L and H [18]. As shown in this report, the function
of BCPI is undoubtedly inhibition of the cysteine proteinase
activity. From these facts, we may be able to propose a new
member of cysteine proteinase inhibitors, which resemble cys-
teine proteinases proregions but are distinct from cystatins.
The two CTLA-2 proteins (CTLA-2 K and L) are closely
related at the amino acid sequences and the CTLA-2 genes are
mapped to the same region of the mouse chromosome, sug-
gesting that the ancestor gene of CTLA-2 has derived from an
ancestor cysteine proteinase gene by partial duplication and
duplicated again very recently to generate the two proteins. At
present, we do not have data to suggest the origin of the
inhibitor gene. But interestingly, for B. mori, there is at least
one more inhibitor protein, BCPI K, which resembles the in-
hibitor cloned here (BCPI L) in the amino acid sequences. The
N-terminal amino acid sequence of BCPI K is as follows: Asp-
Thr-Asp-Pro-Pro5-Arg-His-Tyr-Asp-Leu10-Asn-Gln-Ala-Lys-
Glu15-Leu-Phe-Glu-Ser-Phe20-Val-Lys. In the case of BCPI L,
Asp-1, Pro-4 and Ser-19 are substituted by Glu-1, Thr-4 and
Ile-19, respectively, other amino acid sequences determined to
be identical for both inhibitors. All these results suggest that
the inhibitor gene may have derived from an ancestor cysteine
proteinase gene.
The function of the propeptides in the cysteine proteinases
has been discussed [19,20]. Removal of the propeptide con-
verts the inactive pro-forms of cysteine proteinases to the
enzymatically active forms. Propeptides of procathepsin L
[21^23] and papain precursor [24] inhibit selectively the en-
zyme activity of the corresponding mature enzymes. From
these results, the possibility that one of the functions of the
propeptide is inhibition of enzymatic activity has been pro-
posed. The facts obtained here strongly support this possibil-
ity. The evolutional emergence of the inhibitor gene may be
regarded as a genetic version of the functional propeptide.
There are highly conserved amino acids interspersed in the
sequences among the inhibitor and the propeptides of cysteine
proteinases (Fig. 5). Similar highly conserved amino acids
have been pointed out when the propeptide regions of cysteine
proteinases are compared [17,25]. These results suggest that
amino acid motives in which such highly conserved amino
acids are interspersed serve to inhibit the proteinase activity.
Further studies using recombinant inhibitor proteins are in
progress.
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